GURUFOCUS.COM » STOCK LIST » USA » NAS » GreenLight Biosciences Inc (NAS:GRNA) » Definitions » Financial Strength
Switch to:

GreenLight Biosciences Financial Strength

: 7 (As of Mar. 2022)
View and export this data going back to 2022. Start your Free Trial

GreenLight Biosciences has the Financial Strength Rank of 7.

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3. Altman Z-Score.

GreenLight Biosciences did not have earnings to cover the interest expense. As of today, GreenLight Biosciences's Altman Z-Score is 0.00.


Competitive Comparison

For the Biotechnology subindustry, GreenLight Biosciences's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

GreenLight Biosciences Financial Strength Distribution

For the Biotechnology industry and Healthcare sector, GreenLight Biosciences's Financial Strength distribution charts can be found below:

* The bar in red indicates where GreenLight Biosciences's Financial Strength falls into.



GreenLight Biosciences Financial Strength Calculation

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

GreenLight Biosciences's Interest Expense for the months ended in Mar. 2022 was $-1.07 Mil. Its Operating Income for the months ended in Mar. 2022 was $-36.78 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2022 was $23.69 Mil.

GreenLight Biosciences's Interest Coverage for the quarter that ended in Mar. 2022 is

GreenLight Biosciences did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

2. Debt to revenue ratio. The lower, the better.

GreenLight Biosciences's Debt to Revenue Ratio for the quarter that ended in Mar. 2022 is

Debt to Revenue Ratio=Total Debt (Q: Mar. 2022 ) / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(9.849 + 23.686) / 0
=N/A

3. Altman Z-Score.

Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

The zones of discrimination were as such:

When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.

GreenLight Biosciences has a Z-score of 0.00, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


GreenLight Biosciences  (NAS:GRNA) Financial Strength Explanation

The maximum rank is 10. Companies with rank 7 or higher will be unlikely to fall into distressed situations. Companies with rank of 3 or less are likely in financial distress.

GreenLight Biosciences has the Financial Strength Rank of 7.


GreenLight Biosciences Financial Strength Related Terms

Thank you for viewing the detailed overview of GreenLight Biosciences's Financial Strength provided by GuruFocus.com. Please click on the following links to see related term pages.


GreenLight Biosciences Business Description

GreenLight Biosciences logo
Traded in Other Exchanges
Address
200 Boston Avenue, Suite 3100, Medford, MA, USA, 02155
GreenLight Biosciences Inc is a pre-commercial stage synthetic biology company with a proprietary cell-free ribonucleic acid production platform for the discovery, development, and commercialization of high-performing products to promote healthier plants, foods, and people. The company is developing RNA products for plant and life science applications to advance crop management, plant protection, animal health, vaccine development, and pandemic preparation.
Executives
Keefe Susan officer: CFO & Interim CAO C/O SERACARE LIFE SCIENCES, INC. 375 WEST STREET WEST BRIDGEWATER MA 02379
Obrien Eric director, 10 percent owner C/O GREENLIGHT BIOSCIENCES HOLDINGS, PBC 200 BOSTON AVENUE, SUITE 3100 MEDFORD MA 02155
Walker Matthew Alan director, 10 percent owner C/O GREENLIGHT BIOSCIENCES HOLDINGS, PBC 200 BOSTON AVENUE, SUITE 3100 MEDFORD MA 02155
Schlicher Martha director C/O GREENLIGHT BIOSCIENCES HOLDINGS, PBC 200 BOSTON AVENUE, SUITE 3100 MEDFORD MA 02155
Singleton Mark officer: VP of Technology C/O GREENLIGHT BIOSCIENCES HOLDINGS, PBC 200 BOSTON AVENUE, SUITE 3100 MEDFORD MA 02155
Khan Amin officer: Chief Scientific Officer C/O GREENLIGHT BIOSCIENCES HOLDINGS, PBC 200 BOSTON AVENUE, SUITE 3100 MEDFORD MA 02155
Ortega-valle Marta officer: Chief Business Officer C/O GREENLIGHT BIOSCIENCES HOLDINGS, PBC 200 BOSTON AVENUE, SUITE 3100 MEDFORD MA 02155
Manocha Charu officer: Chief People Officer C/O GREENLIGHT BIOSCIENCES HOLDINGS, PBC 200 BOSTON AVENUE, SUITE 3100 MEDFORD MA 02155
Pardi Jennifer E director 99 HIGH STREET, 12TH FLOOR BOSTON MA 02110
Builders Vision Llc 10 percent owner 110 NW 2ND STREET SUITE 300 BENTONVILLE AR 72712
Kennedy David officer: General Counsel & Secretary 3030 ORCHARD PARKWAY SAN JOSE CA 95134
Cobb Carole B officer: Chief Operating Officer
Mvil, Llc 10 percent owner 22ND FLOOR HANG LUNG CENTRE 2-20 PATERSON STREET CAUSEWAY BAY K3 00000
Cooney Charles L director C/O POLYPORE INTERNATIONAL, INC. 11430 N. COMMUNITY HOUSE ROAD, SUITE 350 CHARLOTTE NC 28277
Zarur Juan Andrey director, officer: President & CEO C/O SOLID BIOSCIENCES, LLC 141 PORTLAND STREET, FIFTH FLOOR CAMBRIDGE MA 02139
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)